Rockwell Medical announces design of Phase III development program for Soluble Ferric Pyrophosphate

Links shared publicly online about this topic.

788
total visits

Rockwell Medical announces design of Phase III development program for Soluble Ferric Pyrophosphate

Rockwell Medical, a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron-deficiency anemia, announced today the design of its Phase III development program for Soluble Ferric Pyrophosphate (SFP) as a continuous iron replacement therapeutic.

View full resource at news-medical.net

Tags: Kidney Health, Urinary System, Kidney Disease, Kidney Failure, End-Stage Renal Disease, Nephrology, disease, Medical